Q-omics provides the consensus-scored TRMT2A profile across patient tissues and cancer cell-line models. TRMT2A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRMT2A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TRMT2A protein abundance shows 19,844 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where TRMT2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT2A survival associations across molecular data types. TRMT2A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT2A RNA expression–survival associations across cancer types. High TRMT2A expression shows unfavorable associations in UVM, ACC, KICH, LIHC, KIRC and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRMT2A RNA expression.
This table summarizes TRMT2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRMT2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT2A shows higher tumor expression in KIRC, COAD, BLCA, HNSC, LIHC and STAD. The KIRC box plot shows higher TRMT2A RNA expression in tumor versus normal tissue (log2 FC = +0.881, t-test p < 0.001).
This table shows molecular features associated with TRMT2A in patient tissues and cancer cell lines. In patient samples, TRMT2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
